These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12063682)

  • 1. Doctor's dilemma: incorporating tumor markers into clinical decision-making.
    Canil CM; Tannock IF
    Semin Oncol; 2002 Jun; 29(3):286-93. PubMed ID: 12063682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
    Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
    Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of serum tumor markers in the management of patients with malignancy.
    Markman M
    J Cancer Res Clin Oncol; 1993; 119(11):635-6. PubMed ID: 7688748
    [No Abstract]   [Full Text] [Related]  

  • 4. Testicular Cancer Biomarkers: A Role for Precision Medicine in Testicular Cancer.
    Leão R; Ahmad AE; Hamilton RJ
    Clin Genitourin Cancer; 2019 Feb; 17(1):e176-e183. PubMed ID: 30497810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum tumor markers.
    Perkins GL; Slater ED; Sanders GK; Prichard JG
    Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response.
    Small EJ; Roach M
    Semin Oncol; 2002 Jun; 29(3):264-73. PubMed ID: 12063679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of vital germ cell tumor cells in short-term cell cultures of primary tumors and of retroperitoneal metastasis--clinical implications.
    Otto T; Virchow S; Fuhrmann C; Steinberg F; Streffer C; Goepel M; Rübben H
    Urol Res; 1997; 25(2):121-4. PubMed ID: 9144879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical evaluation of human prostatic carcinomas for carcinoembryonic antigen, nonspecific cross-reacting antigen, beta-chorionic gonadotrophin, and prostate-specific antigen.
    Purnell DM; Heatfield BM; Trump BF
    Cancer Res; 1984 Jan; 44(1):285-92. PubMed ID: 6197163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients.
    Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoembryonic antigen and carbohydrate antigen 19-9-producing adenocarcinoma of the prostate: report of an autopsy case.
    Kodama S; Itoh H; Ide H; Kataoka H; Takehara T; Nagano M; Hamasuna R; Koono M; Osada Y
    Urol Int; 1999; 63(3):193-7. PubMed ID: 10738193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological markers of cancer. Critical study].
    Bellet D; Bidart JM
    Presse Med; 1993 Apr; 22(14):680-6. PubMed ID: 8511115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of circulating tumor markers].
    Ohkura H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
    Vandenberg TA
    Clin Biochem; 1993 Dec; 26(6):429-30. PubMed ID: 7510220
    [No Abstract]   [Full Text] [Related]  

  • 14. A simple computer program for calculating PSA recurrence in prostate cancer patients.
    Liao Z; Datta MW
    BMC Urol; 2004 Jun; 4():8. PubMed ID: 15207005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of common seric tumor markers in patients with solid cancers.
    Gara S; Boussen H; Ghanem A; Guemira F
    Tunis Med; 2008 Jun; 86(6):579-83. PubMed ID: 19216452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers: value and limitations in the management of cancer patients.
    Bates SE; Longo DL
    Cancer Treat Rev; 1985 Sep; 12(3):163-207. PubMed ID: 2416441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of five tumor markers (AFP, CEA, hCG, hPL and SP1) in monitoring therapy and follow-up of patients with testicular germ cell tumors.
    Szymendera JJ; Zborzil J; Sikorowa L; Leńko J; Kamińska JA; Gadek A
    Oncology; 1983; 40(1):1-10. PubMed ID: 6185897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of marker half-life in relapsed and nonrelapsed nonseminomatous germ cell testicular tumor patients undergoing chemotherapy.
    Keskin S; Ekenel M; Başaran M; Bavbek S
    Am J Clin Oncol; 2012 Aug; 35(4):369-72. PubMed ID: 22814307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of current bio- and molecular-markers in urological cancers].
    Shimazui T; Akaza H
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1008-14. PubMed ID: 15272577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of human chorionic gonadotropin, alpha-fetoprotein, and pregnancy-specific beta-1-glycoprotein in the detection of tumor relapse and partial remission in 126 patients with nonseminomatous testicular germ cell tumors.
    de Bruijn HW; Sleijfer DT; Schraffordt Koops H; Suurmeijer AJ; Marrink J; Ockhuizen T
    Cancer; 1985 Feb; 55(4):829-35. PubMed ID: 2578303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.